Indications and collaborations

After looking over the poster presentation from CTAD it is clear that the amount of indications worth looking into, is far more than we can handle.

Our patent runs out in 2031, so it would be assumed that now is the time to get the ball rolling for as many indications as possible. For that to happen, there would obviously need to be some backing from big pharma, whether it be in the form of acquisition or collaboration.

The systemic review and decision of indications is meant to be announced in q1 2019. To identify what indications can be initiated, it's assumed that they are required to know what funds they have available to them. They have recently been very vocal about ongoing partnership discussions and significant big pharma interest.
Is there a possibility that we may see some form of collaboration to assist with numerous indications in q1? Naturally initiation would be dependant on XanADu results, but it would make sense to have the other trials ready to go.

This is speculation ofcourse, and the more likely partnership would take place after positive results. But as I said, they have been very vocal about their ongoing discussions with partners. Bill has already stated that a partnership prior to results isn't off the table (paraphrasing).

Would love to know what other, more experienced investors have to say on the matter.

Attached is the CTAD poster presentation for those who have not seen it, unfortunately Craig Richies presentation would not upload, apologies.